Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Duration of anticoagulant treatment after venous thromboembolism.
Becattini C, Agnelli G. Becattini C, et al. Among authors: agnelli g. Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):354-7. doi: 10.1159/000083828. Pathophysiol Haemost Thromb. 2003. PMID: 15692243 Free article. Review. No abstract available.
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.
Santamaria MG, Agnelli G, Taliani MR, Prandoni P, Moia M, Bazzan M, Guazzaloca G, Ageno W, Bertoldi A, Silingardi M, Tomasi C, Ambrosio GB; Warfarin Optimal Duration Italian Trial (WODIT) Investigators. Santamaria MG, et al. Among authors: agnelli g. Thromb Res. 2005;116(4):301-6. doi: 10.1016/j.thromres.2004.12.012. Epub 2005 Jan 26. Thromb Res. 2005. PMID: 16038714
Initial treatment of venous thromboembolism.
Becattini C, Agnelli G, Emmerich J, Bura A, Weitz JI. Becattini C, et al. Among authors: agnelli g. Thromb Haemost. 2006 Sep;96(3):242-50. doi: 10.1160/TH06-05-0260. Thromb Haemost. 2006. PMID: 16953263 Review.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators. Agnelli G, et al. Circulation. 2007 Jul 10;116(2):180-7. doi: 10.1161/CIRCULATIONAHA.106.668020. Epub 2007 Jun 18. Circulation. 2007. PMID: 17576867 Clinical Trial.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study.
Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A; Einstein-DVT Dose-Ranging Study investigators. Buller HR, et al. Among authors: agnelli g. Blood. 2008 Sep 15;112(6):2242-7. doi: 10.1182/blood-2008-05-160143. Epub 2008 Jul 11. Blood. 2008. PMID: 18621928 Free article. Clinical Trial.
660 results